Redx Pharma Plc announces that Dr. Thomas Burt, Non-Executive Director, has informed the Board of Directors of the Company ("the Board") of his intention to resign as a Director of the Company with effect from 1 September 2023. Dr. Burt is currently the representative of Sofinnova Crossover 1 SLP ("Sofinnova"), one of the Company's major shareholders. Sofinnova has nominated Dr. Joe Anderson to be their new representative.

It is therefore anticipated that Dr. Anderson will, subject to due diligence and other appointment processes, join the Board following Dr. Burt's resignation becoming effective.